Impact of Focal White Matter Damage on Localized Subcortical Gray Matter Atrophy in Multiple Sclerosis: A 5-Year Study

References

1. 1.↵
   2. Geurts JJ,
   3. Barkhof F

   . Grey matter pathology in multiple sclerosis. Lancet Neurol 2008;7:841–51 doi:10.1016/S1474-4422(08)70191-1 pmid:18703006

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Audoin B,
   3. Zaaraoui W,
   4. Reuter F, et al

   . Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis. J Neurol Neurosurg Psychiatry 2010;81:690–95 doi:10.1136/jnnp.2009.188748 pmid:20392976

   Abstract/FREE Full Text
3. 3.↵
   2. Zivadinov R,
   3. Uher T,
   4. Hagemeier J, et al

   . A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. Mult Scler 2016;22:1709–18 doi:10.1177/1352458516629769 pmid:26883943

   CrossRefPubMed
4. 4.↵
   2. Absinta M,
   3. Vuolo L,
   4. Rao A, et al

   . Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology 2015;85:18–28 doi:10.1212/WNL.0000000000001587 pmid:25888557

   Abstract/FREE Full Text
5. 5.↵
   2. Minagar A,
   3. Barnett MH,
   4. Benedict RH, et al

   . The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology 2013;80:210–19 doi:10.1212/WNL.0b013e31827b910b pmid:23296131

   Abstract/FREE Full Text
6. 6.↵
   2. Kuceyeski AF,
   3. Vargas W,
   4. Dayan M, et al

   . Modeling the relationship among gray matter atrophy, abnormalities in connecting white matter, and cognitive performance in early multiple sclerosis. AJNR Am J Neuroradiol 2015;36:702–09 doi:10.3174/ajnr.A4165 pmid:25414004

   Abstract/FREE Full Text
7. 7.↵
   2. Calabrese M,
   3. Magliozzi R,
   4. Ciccarelli O, et al

   . Exploring the origins of grey matter damage in multiple sclerosis. Nat Rev Neurosci 2015;16:147–58 doi:10.1038/nrn3900 pmid:25697158

   CrossRefPubMed
8. 8.↵
   2. Dziedzic T,
   3. Metz I,
   4. Dallenga T, et al

   . Wallerian degeneration: a major component of early axonal pathology in multiple sclerosis. Brain Pathol 2010;20:976–85 doi:10.1111/j.1750-3639.2010.00401.x pmid:20477831

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Vargas ME,
   3. Barres BA

   . Why is Wallerian degeneration in the CNS so slow? Annu Rev Neurosci 2007;30:153–79 doi:10.1146/annurev.neuro.30.051606.094354 pmid:17506644

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Mühlau M,
    3. Buck D,
    4. Förschler A, et al

    . White-matter lesions drive deep gray-matter atrophy in early multiple sclerosis: support from structural MRI. Mult Scler 2013;19:1485–92 doi:10.1177/1352458513478673 pmid:23462349

    CrossRefPubMed
11. 11.↵
    2. Sepulcre J,
    3. Goñi J,
    4. Masdeu JC, et al

    . Contribution of white matter lesions to gray matter atrophy in multiple sclerosis: evidence from voxel-based analysis of T1 lesions in the visual pathway. Arch Neurol 2009;66:173–79 doi:10.1001/archneurol.2008.562 pmid:19204153

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Sepulcre J,
    3. Sastre-Garriga J,
    4. Cercignani M, et al

    . Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study. Arch Neurol 2006;63:1175–80 doi:10.1001/archneur.63.8.1175 pmid:16908748

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Henry RG,
    3. Shieh M,
    4. Amirbekian B, et al

    . Connecting white matter injury and thalamic atrophy in clinically isolated syndromes. J Neurol Sci 2009;282:61–66 doi:10.1016/j.jns.2009.02.379 pmid:19394969

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Chard DT,
    3. Brex PA,
    4. Ciccarelli O, et al

    . The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study. J Neurol Neurosurg Psychiatry 2003;74:1551–54 doi:10.1136/jnnp.74.11.1551 pmid:14617714

    Abstract/FREE Full Text
15. 15.↵
    2. Kuceyeski A,
    3. Maruta J,
    4. Relkin N, et al

    . The Network Modification (NeMo) tool: elucidating the effect of white matter integrity changes on cortical and subcortical structural connectivity. Brain Connect 2013;3:451–63 doi:10.1089/brain.2013.0147 pmid:23855491

    CrossRefPubMed
16. 16.↵
    2. Reich DS,
    3. Ozturk A,
    4. Calabresi PA, et al

    . Automated vs. conventional tractography in multiple sclerosis: variability and correlation with disability. Neuroimage 2010;49:3047–56 doi:10.1016/j.neuroimage.2009.11.043 pmid:19944769

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Kappus N,
    3. Weinstock-Guttman B,
    4. Hagemeier J, et al

    . Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016;87:181–87 doi:10.1136/jnnp-2014-310051 pmid:25722366

    Abstract/FREE Full Text
18. 18.↵
    2. Zivadinov R,
    3. Ramasamy DP,
    4. Benedict RR, et al

    . Cerebral microbleeds in multiple sclerosis evaluated on susceptibility-weighted images and quantitative susceptibility maps: a case-control study. Radiology 2016;281:884–95 doi:10.1148/radiol.2016160060 pmid:27308776

    CrossRefPubMed
19. 19.↵
    2. Zivadinov R,
    3. Rudick RA,
    4. De Masi R, et al

    . Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239–47 doi:10.1212/WNL.57.7.1239 pmid:11591843

    Abstract/FREE Full Text
20. 20.↵
    2. Gelineau-Morel R,
    3. Tomassini V,
    4. Jenkinson M, et al

    . The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis. Hum Brain Mapp 2012;33:2802–14 doi:10.1002/hbm.21402 pmid:21976406

    CrossRefPubMed
21. 21.↵
    2. Smith SM,
    3. Zhang Y,
    4. Jenkinson M, et al

    . Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479–89 doi:10.1006/nimg.2002.1040 pmid:12482100

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Patenaude B,
    3. Smith S,
    4. Kennedy D, et al

    . A Bayesian model of shape and appearance for subcortical brain. Neuroimage 2011;56:907–22

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Smith SM,
    3. De Stefano N,
    4. Jenkinson M, et al

    . Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001;25:466–75 doi:10.1097/00004728-200105000-00022 pmid:11351200

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Avants BB,
    3. Tustison NJ,
    4. Song G, et al

    . A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage 2011;54:2033–44 doi:10.1016/j.neuroimage.2010.09.025 pmid:20851191

    CrossRefPubMed
25. 25.↵
    2. Fuchs T,
    3. Dwyer M,
    4. Kuceyeski A, et al

    . White matter tract network disruption explains reduced conscientiousness in multiple sclerosis. Hum Brain Mapp 2018 May 8. [Epub ahead of print] doi:10.1002/hbm.24203 pmid:29740964

    CrossRefPubMed
26. 26.↵
    2. Van Waesberghe JH,
    3. Kamphorst W,
    4. De Groot CJA, et al

    . Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999;46:747–54 pmid:10553992

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Zurawski J,
    3. Lassmann H,
    4. Bakshi R

    . Use of magnetic resonance imaging to visualize leptomeningeal inflammation in patients with multiple sclerosis: a review. JAMA Neurol 2017;74:100–09 doi:10.1001/jamaneurol.2016.4237 pmid:27893883

    CrossRefPubMed
28. 28.↵
    2. Louapre C,
    3. Govindarajan ST,
    4. Giannì C, et al

    . Heterogeneous pathological processes account for thalamic degeneration in multiple sclerosis: insights from 7 T imaging. Mult Scler 2017 Aug 1. [Epub ahead of print] doi:10.1177/1352458517726382 pmid:28803512

    CrossRefPubMed
29. 29.↵
    2. Kappos L,
    3. De Stefano N,
    4. Freedman MS, et al

    . Inclusion of brain volume loss in a revised measure of “no evidence of disease activity” (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler 2016;22:1297–305 doi:10.1177/1352458515616701 pmid:26585439

    CrossRefPubMed